These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33054136)

  • 1. Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
    Youssef Y; Karkhanis V; Chan WK; Jeney F; Canella A; Zhang X; Sloan S; Prouty A; Helmig-Mason J; Tsyba L; Hanel W; Zheng X; Zhang P; Chung JH; Lucas DM; Kauffman Z; Larkin K; Strohecker AM; Ozer HG; Lapalombella R; Zhou H; Xu-Monette ZY; Young KH; Han R; Nurmemmedov E; Nuovo G; Maddocks K; Byrd JC; Baiocchi RA; Alinari L
    Haematologica; 2021 Nov; 106(11):2927-2939. PubMed ID: 33054136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.
    Pray BA; Youssef Y; Alinari L
    Exp Hematol; 2022 Dec; 116():18-25. PubMed ID: 36206873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
    Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
    Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
    Nowakowski GS; Czuczman MS
    Am Soc Clin Oncol Educ Book; 2015; ():e449-57. PubMed ID: 25993209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.
    Wu Y; Gu H; Bao Y; Lin T; Wang Z; Gu D; Shen H; Xian H; Fan Y; Mao R
    Cell Biochem Funct; 2022 Jun; 40(4):379-390. PubMed ID: 35411950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA; Smith SM
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct ubiquitination of beta-catenin by Siah-1 and regulation by the exchange factor TBL1.
    Dimitrova YN; Li J; Lee YT; Rios-Esteves J; Friedman DB; Choi HJ; Weis WI; Wang CY; Chazin WJ
    J Biol Chem; 2010 Apr; 285(18):13507-16. PubMed ID: 20181957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
    Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
    Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.